Glucosamine supplement linked to faster Alzheimer's progression in new study

A team of neuroscientists at the University of Florida has uncovered a troubling connection: glucosamine, the over-the-counter supplement that millions of seniors swallow daily for joint pain, appears to accelerate the progression of Alzheimer's disease and related cognitive decline. The finding, published in Nature Metabolism, emerged from a systematic review of patient records spanning twelve years, combined with laboratory evidence from mouse models and human brain tissue that points to a specific metabolic pathway gone awry.

The researchers began with a straightforward question. Glucosamine is ubiquitous in American medicine cabinets—cheap, widely available, and considered safe by most people who take it. Yet no one had systematically asked whether this common supplement might affect the brain in people already experiencing cognitive problems. Using artificial intelligence to sift through deidentified health records from 2012 to 2024, the team identified 4,646 patients at the University of Florida Health system who had been diagnosed with either Alzheimer's disease or mild cognitive impairment. Eight percent of them—nearly 1,900 with established Alzheimer's and 2,750 with milder cognitive problems—reported taking glucosamine.

When the researchers controlled for age, sex, and other demographic factors, the numbers became stark. Patients with mild cognitive impairment who took glucosamine were 25 percent more likely to progress to full dementia. Among those already diagnosed with Alzheimer's disease, glucosamine use was associated with a 25 percent increase in mortality risk—a measure of how quickly the disease advanced toward death. The effect appeared concentrated in people with established disease; glucosamine showed no measurable impact on mortality in the milder cognitive impairment group, suggesting the supplement's harm depends on the brain's existing state of decline.

Ramon Sun, the senior author and director of the Center for Advanced Spatial Biomolecule Research at the university's McKnight Brain Institute, framed the stakes plainly: millions of Americans living with Alzheimer's and related dementias are actively taking a supplement that could be worsening their condition. The question then became why. Glucosamine is a naturally occurring sugar-related molecule small enough to cross the blood-brain barrier. Once inside the brain, it feeds into metabolic pathways that attach sugar structures to proteins—a process essential for normal cellular function but, the research suggests, dangerously overactive in Alzheimer's brains.

To test this hypothesis, Sun's team used advanced spatial imaging technology developed in his laboratory to examine thousands of molecules produced when the body metabolizes food and drugs. In genetically modified mice, glucosamine supplementation significantly increased the attachment of sugar residues to proteins in brain cells. The treated mice showed worsening deficits in social memory—their ability to recognize and remember other mice. When researchers chemically suppressed this sugar-tagging process, memory improved. The pattern held in human tissue: brain specimens from Alzheimer's patients in the university's neuromedicine brain bank showed substantially more of these sugar attachments compared with normal controls.

Matt Gentry, chair of the Department of Biochemistry and Molecular Biology and a co-author, described the implications carefully. Proteins are the cell's molecular machines, and many require sugar tags applied with precision to fold correctly, travel to the right location, and perform their function. In Alzheimer's brains, this sugar-tagging system appears overactive—the brain is adding too many of these structures, and this excess appears to contribute to disease rather than protect against it. The finding suggests that metabolic dysfunction is not merely a side effect of Alzheimer's pathology but a driving force behind it.

Sun acknowledged that the results are preliminary and require validation through human clinical trials before they can reshape clinical practice. The electronic health record analysis shows association, not causation. Yet the evidence from three independent sources—patient records, mouse models, and human brain tissue—points in the same direction. The discovery opens a new avenue for intervention: if altered metabolism contributes significantly to Alzheimer's progression, then addressing that metabolic defect could complement existing treatments focused on clearing the plaques and tangles that have long been the disease's most visible hallmarks. For the millions of seniors currently taking glucosamine, the question of whether to continue has suddenly become more complicated.